Jpmorgan Chase & CO Adamis Pharmaceuticals Corp Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.1 - $0.3 $1 - $3	-10 Reduced 2.49%	392 $0
Q4 2022 Feb 13, 2023	SELL	$0.14 - $0.22 $22 - $34	-158 Reduced 28.21%	402 $0
Q3 2022 Nov 14, 2022	SELL	$0.24 - $0.54 $6,777 - $15,249	-28,240 Reduced 98.06%	560 $0
Q2 2022 Aug 11, 2022	SELL	$0.34 - $0.57 $19,031 - $31,905	-55,975 Reduced 66.03%	28,800 $14,000
Q1 2022 May 11, 2022	SELL	$0.55 - $0.73 $73,588 - $97,672	-133,798 Reduced 61.21%	84,775 $48,000
Q4 2021 Feb 10, 2022	BUY	$0.57 - $1.23 $109,669 - $236,655	192,403 Added 735.2%	218,573 $132,000
Q3 2021 Nov 12, 2021	BUY	$0.92 - $1.18 $24,076 - $30,880	26,170 New	26,170 $25,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.